Online inquiry

IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10508MR)

This product GTTS-WQ10508MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ10508MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15971MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ9181MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN853
GTTS-WQ789MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Ab-2
GTTS-WQ13MR IVTScrip™ mRNA-Anti-S, 2130(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 2130
GTTS-WQ14200MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RG4934
GTTS-WQ5543MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CDP7657
GTTS-WQ8709MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ8231MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HLX-06
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW